Non-Surgical Therapy PRV111 Shows High Response Rate in Early-Stage Oral Cancer Trial

Privo Technologies has announced positive results from its Phase 2 CLN-004 trial for PRV111, a nanoengineered, cisplatin-releasing patch for the treatment of non-invasive oral cancer and high-grade dysplasia. The study reported a 95.5% pathologic complete response (pCR) rate, with 21 out of 22 evaluable patients achieving complete clearance or downgrading of lesions. All patients avoided the need for standard-of-care surgery, and no recurrences have been observed with a median follow-up of 14 months.